Skip to Main Content

Filter:

Editors Choice

1 Results

Editorial
EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents
Journal of Thoracic Oncology
Vol. 17Issue 9p1067–1069Published in issue: September, 2022
- Nicolas Girard
Cited in Scopus: 0
In this issue of the Journal of Thoracic Oncology, Piccirillo et al.¹ report the results of the BEVERLY trial, a randomized phase 3 study that reveals the progression-free survival (PFS) benefit of bevacizumab to erlotinib as first-line treatment for Italian patients with metastatic NSCLC with common EGFR mutations. In this large study, after a median follow-up of 36.3 months, median investigator-assessed PFS was 15.4 months with erlotinib plus bevacizumab and 9.6 months with erlotinib alone (hazard ratio = 0.66, 95% confidence interval: 0.47–0.92).